1. Home
  2. NKGN vs ATIF Comparison

NKGN vs ATIF Comparison

Compare NKGN & ATIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • ATIF
  • Stock Information
  • Founded
  • NKGN 2017
  • ATIF 2015
  • Country
  • NKGN United States
  • ATIF United States
  • Employees
  • NKGN N/A
  • ATIF N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • ATIF Professional Services
  • Sector
  • NKGN Health Care
  • ATIF Consumer Discretionary
  • Exchange
  • NKGN Nasdaq
  • ATIF Nasdaq
  • Market Cap
  • NKGN 14.1M
  • ATIF 9.8M
  • IPO Year
  • NKGN N/A
  • ATIF 2019
  • Fundamental
  • Price
  • NKGN $0.25
  • ATIF $1.00
  • Analyst Decision
  • NKGN
  • ATIF
  • Analyst Count
  • NKGN 0
  • ATIF 0
  • Target Price
  • NKGN N/A
  • ATIF N/A
  • AVG Volume (30 Days)
  • NKGN 352.0K
  • ATIF 203.1K
  • Earning Date
  • NKGN 11-12-2024
  • ATIF 11-11-2024
  • Dividend Yield
  • NKGN N/A
  • ATIF N/A
  • EPS Growth
  • NKGN N/A
  • ATIF N/A
  • EPS
  • NKGN N/A
  • ATIF N/A
  • Revenue
  • NKGN N/A
  • ATIF $500,000.00
  • Revenue This Year
  • NKGN N/A
  • ATIF N/A
  • Revenue Next Year
  • NKGN N/A
  • ATIF N/A
  • P/E Ratio
  • NKGN N/A
  • ATIF N/A
  • Revenue Growth
  • NKGN N/A
  • ATIF N/A
  • 52 Week Low
  • NKGN $0.25
  • ATIF $0.58
  • 52 Week High
  • NKGN $5.10
  • ATIF $1.50
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 21.48
  • ATIF 52.71
  • Support Level
  • NKGN $0.36
  • ATIF $0.76
  • Resistance Level
  • NKGN $0.44
  • ATIF $1.50
  • Average True Range (ATR)
  • NKGN 0.04
  • ATIF 0.20
  • MACD
  • NKGN 0.00
  • ATIF 0.00
  • Stochastic Oscillator
  • NKGN 0.00
  • ATIF 34.73

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About ATIF ATIF Holdings Limited

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: